PTC Therapeutics (PTCT) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PTC Therapeutics (PTCT) has outperformed Summit Therapeutics (SMMT) over the past year, losing 2.0% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with +69.9% for PTCT. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $5.40 billion), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTCT | SMMT |
|---|---|---|
| Share price | $64.70 | $17.59 |
| Market cap | $5.40B | $14.03B |
| 1-day change | +3.42% | +2.45% |
| YTD return | -14.82% | +0.57% |
| 1-year return | -1.98% | -22.34% |
| 5-year return | +69.86% | +241.55% |
| Forward P/E | 27.30 | — |
| EPS (TTM) | $-0.67 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.73B | — |
| Revenue growth (YoY) | +114.51% | — |
| Net income (latest FY) | $682.64M | $-1.08B |
| Operating margin | 50.09% | — |
| Net margin | 39.44% | — |
| 52-week high | $90.87 | $29.23 |
| 52-week low | $61.23 | $12.07 |
| Distance from 52-week high | -28.80% | -39.82% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +56.21% | +69.30% |
| Average volume | 1.14M | 5.87M |
| Shares outstanding | 83.46M | 797.75M |
| Employees | 991 | 265 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Summit Therapeutics is about 2.6 times larger than PTC Therapeutics by market value ($14.03B vs $5.40B).
- PTCT has outperformed SMMT by 20.4 percentage points over the past year.
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Healthcare · Biotechnology · 991 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Healthcare · Biotechnology · 265 employees
PTCT vs SMMT FAQ
Which is bigger, PTC Therapeutics or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $5.40B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, PTCT or SMMT?
PTCT returned -1.98% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are PTC Therapeutics and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.